AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03453333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2D laparoscope
Description: For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
Study NCT02292732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 0.5 mg
Description: Each tablet will contain GSK1120212B equivalent to 0.5 mg of Trametinib. Tablets are yellow, oval, biconvex, film-coated (4.85 x 8.86 millimeter \[mm\]) to be taken orally and once daily
Study NCT00771680 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency at the discretion of the physician following clinical practice
Study NCT02292732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 2 mg
Description: Each tablet will contain GSK1120212B equivalent to 2 mg Trametinib. Tablets are pink, round, biconvex and film-coated tablets (7.5 mm in diameter) to be taken orally and once daily.
Study NCT02292732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORTHO-NOVUM® tablet 1/35
Description: Each peach tablet will contain 1 mg of NE and 0.035 mg of EE. Other inactive ingredients will include lactose, magnesium stearate and pregelatinized corn starch
Study NCT02292732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each green tablet will contain only inert ingredients: D\&C yellow No. 10 Aluminum Lake, FD\&C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, microcrystalline cellulose, and pregelatinized cornstarch. The tablets are to be taken orally and once daily
Study NCT00771680 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency at the discretion of the physician following clinical practice
Study NCT00771680 — intervention group
Intervention type: DRUG
Intervention: insulin aspart
Description: Start dose and frequency at the discretion of the physician following clinical practice
Study NCT01501318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized feedback report
Description: Participants receive the personalized feedback report but no additional education.
Study NCT01501318 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized feedback report plus education
Description: Participants receive the personalized feedback report plus education. This is the currently implemented service approach.
Study NCT03917290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Description: Training will be conducted with a research assistant under the supervision of Dr. Howell (PI), a certified athletic trainer, who will meet with participants either at the individual or small group level (3-4 participants maximum). Training will be done within the Children's Hospital Colorado network-of-care locations, dependent on the location of participants. Due to in-person restrictions that have resulted from COVID-19, participants may also complete the intervention via remote (virtual) training sessions.
Study NCT04133844 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Blood sample collection from a peripheral catheter at ECMO initiation (H0), then 2h, 6h, 12h, 24h and daily from day 2 to day 7 or at ECMO discontinuation
Study NCT03474159 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Aortic distensibility measured in MRI at the Valsalva sinus and at the ascending tubular aortic level
Study NCT03474159 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transthoracic echocardiography
Description: Aortic distensibility measured in TTE of the same segments in TM and in B mode
Study NCT03474159 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Echography UltraFast
Description: Carotid pulse rate measured on carotid arteries by UF
Study NCT01235039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject®25
Description: Two vial presentation for reconstitution and single dose of 12 IU subcutaneous injection and 25 IU/mL
Study NCT01235039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject®7
Description: One vial presentation and single dose of 12 U for subcutaneous injection and 100 IU/mL
Study NCT01235039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: One vial presentation and single dose of 12 IU for subcutaneous injection and 100 IU/mL
Study NCT02093078 — intervention group
Intervention type: BEHAVIORAL
Intervention: CARD
Description: Intervention: CARD~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay.
Study NCT03372395 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lactobacillus rhamnosus BMX 54
Description: Given once a day for 10 days, once every 3 days for 20 days and then once every 5 days for other 2 months in all patients (probiotics implementation for 3 months comprehensively).
Study NCT03372395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus BMX 54
Description: Given once a day for 10 days, once every 3 days for 20 days and then once every 5 days for other 2 months in all patients (probiotics implementation for 3 months comprehensively).
Study NCT00677170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN4924
Description: IV dose escalation for 5 consecutive days followed by a rest period of 16 days for a 21 day cycle. Treated may continue until disease progression or unacceptable toxicity develops.
Study NCT01262729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutical hypothermia
Description: Patients after successful cardiopulmonary resuscitation will be treated in accordance to international guidelines (Guidelines 2005 on cardiopulmonary resuscitation. Resuscitation 2005; 67: S7-S23)
Study NCT01262729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutical hypothermia
Description: Patients after successful cardiopulmonary resuscitation will be treated in accordance to international guidelines (Guidelines 2005 on cardiopulmonary resuscitation. Resuscitation 2005; 67: S7-S23)
Study NCT01262729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon Inhalation
Description: Patients after successful cardiopulmonary resuscitation will be inhalated with 65-70% Xenon within 2 hours additional to therapeutical hypothermia
Study NCT02480855 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire and feedback
Study NCT00480363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maintenance with lower doses of lenalidomide and dexamethasone
Description: After 9 cycles of lenalidomide and dexamethasone, it follows with lower doses for maintenance
Study NCT04359186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Interruption Arm
Description: Individuals with HIV on suppressive ART will interrupt their ART.
Study NCT04085263 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The patients in this group will receive sham rhomboid intercostal and subserratus plane.
Study NCT04085263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhomboid intercostal and subserratus plane block group
Description: The patients in this group will be receive real ultrasound-guided rhomboid intercostal and subserratus plane.
Study NCT00945971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The intervention group will engage in exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be used at the start and in the end of this study.
Study NCT04141293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alveolar recruitment
Description: Alveolar recruitment is a procedure to re-expand collapsed lung regions with the transient increment in transpulmonary pressure.
Study NCT00534521 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Tibial Nerve Device
Description: The PTNS device (Urgent® PC) is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve (PTNS). It is a combination of a stimulator and a lead set. The stimulator is a battery powered, external pulse generator and is designed, constructed, and manufactured for multiple use in conjunction with the lead set. The lead set (comprised of the lead wires, needle electrode, and alcohol pad) transfers the electrical current from the stimulator to the tibial nerve via the needle electrode. The tibial nerve travels up the leg to the sacral nerve plexus which regulates the bladder and pelvic floor function.
Study NCT01681446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon-alpha (IFN-alpha)
Description: interferon-alpha is intramuscular injected 30 μg three times a week or 50 μg twice a week for 18 months
Study NCT01621334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: Two personal feedback sessions with counselor using motivational interviewing strategies.
Study NCT01621334 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational information
Description: Educational brochure about legal, health and behavioral effects of intimate partner violence, substance abuse, and HIV risky behaviors
Study NCT02716714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ingenol mebutate gel 0.015%
Description: -Face or Scalp arm (Referred to Face/Scalp arm): Apply ingenol mebutate gel 0.015% once daily for 3 consecutive days
Study NCT02716714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ingenol mebutate gel 0.05%
Description: -Trunk or Extremities arm (Referred to Trunk/Extremities arm): Apply ingenol mebutate gel 0.05% once daily for 2 consecutive days
Study NCT05494710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bleomycin electrosclerotherapy treatment
Description: The combination of Bleomycin and electroporation of the treated area which is called electrochemotherapy (ECT).
Study NCT04666948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vancomycin model-informed precision dosing
Description: A CE labelled dosing calculator is used for a priori and a posteriori calculation of vancomycin dose using a target AUC between 400-600 mg\*h/L
Study NCT04666948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin treatment
Study NCT04666948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin treatment
Study NCT01904695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbs
Description: Herbs 180ml by mouth every 12 hours for 8 weeks
Study NCT01904695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihypertensive drugs
Description: Thiazide diuretics and ACE inhibitor and β-blocker in different dosage determined by the physician for 8 weeks
Study NCT01904695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Description: Thiazide diuretics and ACE inhibitor and β-blocker in different dosage determined by the physician for 8 weeks
Study NCT04181294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family meetings using time limited trials as default ICU communication and care planning approach
Description: Providers will be trained using didactics, focus groups, and simulations using actors as family members. A TLT protocol and checklist will be used to facilitate family meetings. A coordinator will schedule family meetings. Routine feedback sessions will be held with the local champions.
Study NCT03177993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 drug dose - IDA
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Participants excluded from ivermectin will receive a topical dose of permethrin cream.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies
Study NCT03177993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 drug dose - IDA with second dose of ivermectin
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Eight days after treatment participants will be given a second dose of ivermectin alone.~Participants excluded from ivermectin will receive a topical dose of permethrin cream both on day 0 and day 8.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies
Study NCT03177993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 drug dose - DA
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA).~If scabies is present in the participant or a household member permethrin cream will be provided 8 days after dose of DA.~Exclusion criteria for diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies
Study NCT01220908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Volume Reduction Coil (LVRC)
Description: Implantation of Lung Volume Reduction Coil(s) (LVRC)
Study NCT01220908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coils
Description: Lung Volume Reduction Coil(s)
Study NCT00534521 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: This 2- piece needle, comprised of a needle handle and blunt-tip shaft feels like a slight prick when touched to the skin. However the shaft retracts as it appears to enter the skin but the skin is not punctured. The Streitberger needle specifically activates the dorsolateral prefrontal cortex, which is associated with the placebo effect.
Study NCT03056716 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Silastic vs conventional drain in thoracic surgery
Description: Apical drains will be identical in size and material, and the basal drains will be different in groups. The patients will be followed for daily amounts of fluid drainage, duration of air leaks and fluid drainage, and duration of hospitalization, and the results will be compared statistically to asses any possible relationships with the outcome and the type of basal drain used.
Study NCT03056716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Silastic vs conventional drain in thoracic surgery
Description: Apical drains will be identical in size and material, and the basal drains will be different in groups. The patients will be followed for daily amounts of fluid drainage, duration of air leaks and fluid drainage, and duration of hospitalization, and the results will be compared statistically to asses any possible relationships with the outcome and the type of basal drain used.
Study NCT04506346 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: difficult tracheal intubation
Description: Grade Ⅲ or Ⅳ according to Cormach-Lehane Grading of laryngoscopic view
Study NCT01602315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719 as film-coated (FC) whole tablets
Description: Oral alpha-specific PI3K inhibitor
Study NCT01059942 — intervention group
Intervention type: OTHER
Intervention: mock handoff exposure
Description: Attending and house-staff physicians will analyze six video scenarios using the Hand-off CEX, rating each of the dimensions of hand-off competence for both the senders and receivers of the mock hand-off.
Study NCT01059942 — intervention group
Intervention type: OTHER
Intervention: Introduction of CEX tool in Actual Hand-offs
Description: We will teach hospitalist physicians and house-staff how to utilize the Hand-off CEX in conducting their own hand-offs.
Study NCT02280915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Savoury food product
Study NCT01602315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719 as dispersible tablets (DT)
Description: New formulation of the oral alpha-specific PI3K inhibitor
Study NCT01602315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Recombinant chimeric monoclonal antibody driven against EGFR
Study NCT01805258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: The regimen containing Nevirapine: 3TC/ZDV 150/300 mg 1 tablet BID + NEVIRAPINE 200 mg qD for 2 weeks then 200mg BID
Study NCT01602315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719 drink suspension
Description: Oral alpha-specific PI3K inhibitor
Study NCT01267123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trendelenburg position
Description: The patient will be placed in the Trendelenburg position with a 15 degree angle of inclination
Study NCT01267123 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard care
Description: The patient will be placed in the standard horizontal position
Study NCT03890302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB704A
Description: Administered by IV infusion
Study NCT03890302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion
Study NCT04020120 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: answer questionnaires
Study NCT04180982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640 dose1 plus Febuxostat dose1
Description: Tablet,dose1,QD
Study NCT04180982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640 dose1 plus Febuxostat dose2
Description: Tablet,dose1, dose2 QD
Study NCT04180982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640 dose2 plus Febuxostat dose3
Description: Tablet,dose2, dose3 QD
Study NCT03574220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IV every 21 days over 6 months
Study NCT03574220 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: 50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-14 days
Study NCT02405455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerclage
Description: Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it.
Study NCT02405455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Description: The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
Study NCT01855009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MannaBears
Description: Subjects will be administered 4 MannaBears daily
Study NCT01855009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AlgaeCal Calcium
Description: Subjects will be administered 750 mg AlgaeCal Calcium
Study NCT01855009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate
Description: Subjects will be administered 1000 mg calcium carbonate
Study NCT01855009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Subjects will be administered 800 IU vitamin D3
Study NCT03156023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozibafusp Alfa
Description: Administered by subcutaneous injection once every 2 weeks.
Study NCT03156023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection once every 2 weeks.
Study NCT03200522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prudent diet
Description: Six days of meals provided with high amounts of fruits and vegetables, whole grains, fiber, omega-3 fatty acids, low-fat dairy products, and overall high levels of antioxidants.
Study NCT03200522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western diet
Description: Six days of meals provided with high amounts of processed foods, fast foods, sweets, omega-6 fatty acids, and a low intake of fiber.